11.13
price down icon2.11%   -0.24
after-market Dopo l'orario di chiusura: 11.13
loading
Precedente Chiudi:
$11.37
Aprire:
$11.41
Volume 24 ore:
3.56M
Relative Volume:
0.79
Capitalizzazione di mercato:
$8.10B
Reddito:
$125.68M
Utile/perdita netta:
$4.81B
Rapporto P/E:
1.9699
EPS:
5.65
Flusso di cassa netto:
$-781.21M
1 W Prestazione:
-0.36%
1M Prestazione:
-5.92%
6M Prestazione:
+2.58%
1 anno Prestazione:
+11.30%
Intervallo 1D:
Value
$11.12
$11.48
Intervallo di 1 settimana:
Value
$11.00
$11.48
Portata 52W:
Value
$9.69
$13.05

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name
Nome
Roivant Sciences Ltd
Name
Telefono
441-295-5950
Name
Indirizzo
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Name
Dipendente
908
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
ROIV's Discussions on Twitter

Confronta ROIV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ROIV
Roivant Sciences Ltd
11.13 8.10B 125.68M 4.81B -781.21M 5.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
461.68 118.90B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
672.98 73.95B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
655.13 39.81B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
271.31 34.99B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
123.77 29.67B 3.30B -501.07M 1.03B -2.1146

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-02-15 Iniziato Wolfe Research Outperform
2024-01-05 Iniziato Piper Sandler Overweight
2023-12-12 Iniziato Deutsche Bank Buy
2023-10-17 Iniziato Guggenheim Buy
2023-06-08 Iniziato BofA Securities Neutral
2022-10-27 Iniziato JP Morgan Overweight
2022-05-23 Iniziato SVB Leerink Outperform
2022-04-29 Iniziato Cantor Fitzgerald Overweight
2021-12-15 Iniziato Goldman Buy
2021-11-08 Iniziato H.C. Wainwright Buy
2021-10-28 Iniziato Citigroup Buy
2021-10-26 Iniziato Cowen Outperform
2021-10-26 Iniziato Jefferies Buy
2021-10-26 Iniziato Truist Buy
Mostra tutto

Roivant Sciences Ltd Borsa (ROIV) Ultime notizie

pulisher
Feb 01, 2025

Roivant Sciences (NASDAQ:ROIV) Upgraded to "Strong-Buy" at Cantor Fitzgerald - MarketBeat

Feb 01, 2025
pulisher
Jan 28, 2025

Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching - MarketBeat

Jan 28, 2025
pulisher
Jan 28, 2025

Trump Index: 6 Companies Linked to Trump's Cabinet Worth Watching - Benzinga

Jan 28, 2025
pulisher
Jan 28, 2025

Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Jan 28, 2025
pulisher
Jan 25, 2025

Roivant sciences president Eric Venker sells $1.13 million in shares - MSN

Jan 25, 2025
pulisher
Jan 24, 2025

Zweig DiMenna Associates LLC Takes Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Jan 24, 2025
pulisher
Jan 23, 2025

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,128,000.00 in Stock - MarketBeat

Jan 23, 2025
pulisher
Jan 23, 2025

Why Is Andreas Halvorsen Bullish On Roivant Sciences Ltd. (ROIV) Now? - Yahoo Finance

Jan 23, 2025
pulisher
Jan 21, 2025

How Rich Is This Indian-Origin Entrepreneur Who Took On Donald Trump But Is Now…? Check His Net Worth - News24

Jan 21, 2025
pulisher
Jan 20, 2025

What Is Vivek Ramaswamy’s net worth? The Indian American man who took on Trump and then became a confidante - The Financial Express

Jan 20, 2025
pulisher
Jan 19, 2025

Trump Inauguration: Who Is Vivek Ramaswamy and what’s his role in Trump 2.0? - The Financial Express

Jan 19, 2025
pulisher
Jan 18, 2025

Roivant Sciences Sees Unusually High Options Volume (NASDAQ:ROIV) - MarketBeat

Jan 18, 2025
pulisher
Jan 17, 2025

Roivant Sciences Ltd. Trade Ideas — LS:A3C4MS - TradingView

Jan 17, 2025
pulisher
Jan 16, 2025

Roivant sciences increases stake in Immunovant with $336.9 million purchase - Investing.com India

Jan 16, 2025
pulisher
Jan 15, 2025

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Acquires $336,900,200.00 in Stock - MarketBeat

Jan 15, 2025
pulisher
Jan 15, 2025

Roivant sciences increases stake in Immunovant with $336.9 million purchase By Investing.com - Investing.com Nigeria

Jan 15, 2025
pulisher
Jan 14, 2025

Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Acquired by JPMorgan Chase & Co. - Defense World

Jan 14, 2025
pulisher
Jan 12, 2025

Is Roivant Sciences (ROIV) the Best Medical Stock to Buy Under $20? - Insider Monkey

Jan 12, 2025
pulisher
Jan 11, 2025

12 Best Medical Stocks To Buy Under $20 - Insider Monkey

Jan 11, 2025
pulisher
Jan 11, 2025

Nordea Investment Management AB Raises Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Jan 11, 2025
pulisher
Jan 10, 2025

ROIVWroivw Latest Stock News & Market Updates - StockTitan

Jan 10, 2025
pulisher
Jan 08, 2025

ROIV Crosses Below Key Moving Average Level - Nasdaq

Jan 08, 2025
pulisher
Jan 07, 2025

Arbutus could benefit from Big Pharma bird flu vaccines: Jefferies - MSN

Jan 07, 2025
pulisher
Jan 06, 2025

Why Ramaswamy Says America Needs a Cultural Shift Towards Excellence for the Sake of US Students - The Times of India

Jan 06, 2025
pulisher
Jan 03, 2025

Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $17.93 Consensus Target Price from Analysts - MarketBeat

Jan 03, 2025
pulisher
Jan 03, 2025

Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Jan 03, 2025
pulisher
Jan 02, 2025

Why Roivant Sciences Ltd. (ROIV) Is Skyrocketing - Yahoo Finance

Jan 02, 2025
pulisher
Jan 01, 2025

10 Firms End 2024 Stronger With Impressive Gains - Insider Monkey

Jan 01, 2025
pulisher
Jan 01, 2025

Strategic Sale: Eric Venker Decides To Exercise Options Worth $3.86M At Roivant Sciences - Benzinga

Jan 01, 2025
pulisher
Dec 31, 2024

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $2,050,704.16 in Stock - MarketBeat

Dec 31, 2024
pulisher
Dec 31, 2024

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 176,900 Shares of Stock - MarketBeat

Dec 31, 2024
pulisher
Dec 31, 2024

Roivant Sciences' president sells common shares worth $4.1 million - Investing.com India

Dec 31, 2024
pulisher
Dec 30, 2024

Principal Financial Group Inc. Has $11.65 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Dec 30, 2024
pulisher
Dec 27, 2024

Roivant Sciences' CIO Mayukh Sukhatme sells $10.6m in shares - Investing.com India

Dec 27, 2024
pulisher
Dec 26, 2024

Eric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat

Dec 26, 2024
pulisher
Dec 26, 2024

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CIO Sells 689,495 Shares of Stock - MarketBeat

Dec 26, 2024
pulisher
Dec 26, 2024

Mayukh Sukhatme Sells 185,946 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat

Dec 26, 2024
pulisher
Dec 26, 2024

Roivant sciences president Eric Venker sells $1.15 million in shares By Investing.com - Investing.com Nigeria

Dec 26, 2024
pulisher
Dec 26, 2024

Roivant Sciences’ CIO Mayukh Sukhatme sells $10.6m in shares By Investing.com - Investing.com Nigeria

Dec 26, 2024
pulisher
Dec 26, 2024

Roivant Sciences' CIO Mayukh Sukhatme sells $10.6m in shares By Investing.com - Investing.com South Africa

Dec 26, 2024
pulisher
Dec 26, 2024

Roivant sciences president Eric Venker sells $1.15 million in shares - Investing.com

Dec 26, 2024
pulisher
Dec 21, 2024

Barclays PLC Buys 75,609 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat

Dec 21, 2024
pulisher
Dec 20, 2024

Mayukh Sukhatme Sells 412,584 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat

Dec 20, 2024

Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$39.42
price down icon 3.95%
$351.17
price down icon 0.32%
$21.50
price down icon 3.85%
$5.30
price down icon 2.03%
biotechnology ONC
$224.99
price down icon 0.84%
$123.77
price up icon 2.39%
Capitalizzazione:     |  Volume (24 ore):